目的 探讨桂龙咳喘宁胶囊联合硫酸沙丁胺醇吸入气雾剂治疗支气管哮喘的临床疗效。方法 选取2020年1月—2021年6月开封市第二中医院收治的114例支气管哮喘患者，按照随机数字表法将114例患者分为对照组和治疗组，每组各57例。对照组雾化吸入硫酸沙丁胺醇吸入气雾剂，200 μg/次，3次/d。治疗组患者在对照组基础上口服桂龙咳喘宁胶囊，1.5 g/次，3次/d。两组患者连续治疗1个月。观察两组的临床疗效，比较两组的临床症状消失时间、肺功能指标和血清中透明质酸（HA）、转化生长因子-β₁（TGF-β₁）、碱性成纤维细胞生长因子（BFGF）水平。结果 治疗后，治疗组总有效率（94.74%）明显高于对照组总有效率（82.46%）（P<0.05）。治疗后，治疗组患者咳嗽、咯痰、哮鸣音消失时间明显短于对照组（P<0.05）。治疗后，两组的第一秒用力呼气量占用力肺活量比值（FEV1/FVC）、用力呼出25%肺活量的呼气流量占预计值百分比（FEF25% pred）显著升高，呼气流速峰值（PEFR）显著降低（P<0.05）；且治疗组的FEV1/FVC、FEF25% pred高于对照组，PEFR低于对照组（P<0.05）。治疗后，两组的血清HA、TGF-β₁、BFGF水平均显著降低（P<0.05），且治疗组血清HA、TGF-β₁、BFGF水平比对照组降低更显著（P<0.05）。结论 桂龙咳喘宁胶囊联合硫酸沙丁胺醇吸入气雾剂可提高支气管哮喘的临床疗效，减轻临床症状，提高肺功能指标，降低血清HA、TGF-β1、BFGF水平，治疗安全性良好。

Objective To investigate the clinical efficacy of Guilong Kechuanning Capsules combined with Salbutamol Sulfate Inhalation Aerosol in treatment of bronchial asthma. Methods Patients (114 cases) with bronchial asthma in Kaifeng Second Hospital of Traditional Chinese Medicine from January 2020 to June 2021 were randomly divided into control and treatment groups, and each group had 57 cases. Patients in the control group were atomization inhalation administered with Salbutamol Sulfate Inhalation Aerosol, 200 μg/time, three times daily. Patients in the treatment group were po administered with Guilong Kechuanning Capsules on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the disappearance time of clinical symptoms, pulmonary function indexes, and the levels of HA, TGF-β₁, and BFGF in two groups were compared. Results After treatment, the total effective rate of the treatment group (94.74%) was significantly higher than that of the control group (82.46%) (P<0.05). After treatment, the disappearance time of cough, expectoration, and wheezing in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the FEV1/FVC and FEF25% pred in two groups were significantly increased, but the PEFR in two groups were significantly decreased (P<0.05). The FEV1/FVC and FEF25% pred in the treatment group were higher than those in the control group, but the PEFR in the treatment group was lower than those in the control group (P<0.05). After treatment, the serum levels of HA, TGF-β₁, and BFGF of two groups were significantly decreased (P<0.05), and the serum levels of HA, TGF-β₁, and BFGF in the treatment group were significantly lower than those in the control group (P<0.05).Conclusion Guilong Kechuanning Capsules combined with Salbutamol Sulfate Inhalation Aerosol can improve the curative effect of bronchial asthma, reduce clinical symptoms, improve pulmonary function indexes, and reduce the serum levels of HA, TGF-β₁, and BFGF, with good safety.

R974

河南省医学科技攻关计划项目（LHGJ2020935）